This paper mainly asks: in breast cancer, which circulating tumor cell (CTC) signals are actually more informative for metastatic risk and later prognosis? Many conventional CTC workflows focus primarily on epithelial markers such as EpCAM. Yet once tumor cells enter a metastasis-related process, their phenotype may gradually change. If detection depends too heavily on a single epithelial signal, the cell populations with the greatest invasive and disseminating potential may be underestimated.
The study published in MDPI Diseases by Good Future and Chung Shan Medical University Hospital addressed this question using the Chiline CATCH® automated negative selection platform. Instead of starting by positively enriching only one predefined tumor phenotype, the workflow first removes normal blood cells and then evaluates the retained non-blood-cell fraction using both EpCAM and CSV (cell-surface vimentin). That design matters because it follows a preserve-first, interpret-next logic rather than assuming in advance which phenotype deserves attention.
The key result was that CSV+ CTCs, not EpCAM+ CTCs, were associated with higher metastatic risk in breast cancer. This matters because CSV is more closely associated with mesenchymal-like or metastasis-related phenotypes. In other words, once the clinical question moves beyond “are there CTCs?” to “which CTCs deserve closer attention?”, the CSV+ population appears to provide stronger risk-discrimination value.
Numerically, a threshold of more than 4.5 CSV+ CTCs per 2 mL of blood identified patients at higher metastatic risk with a sensitivity of 0.56 and a specificity of 0.92. The value here is not that the assay should be reduced to one cut-off alone, but that the relatively high specificity gives the signal meaningful discriminative weight. For risk-stratification settings, that is more useful than a vague indication that something abnormal may be present.
The paper also compared CSV+ CTCs with conventional serum tumor markers, including CA 15-3, CA 125, and CEA. CSV+ CTCs performed better than those markers in identifying higher-risk patients, and the combined use improved stratification further. This suggests that CTC-based information is not simply a replacement for existing markers, but a complementary layer that may reflect tumor-cell state more directly than serum markers alone.
Another important observation was that CSV+ CTC counts of 5 cells or more per 2 mL of blood were significantly associated with worse progression-free survival. That moves the relevance of CSV+ CTCs beyond cross-sectional risk categorization and toward prognosis and longitudinal follow-up. With additional validation, this type of signal could become increasingly important in how breast-cancer monitoring strategies are structured.
From a platform perspective, this study also shows that the CTC platform itself directly affects what can ultimately be seen. If the enrichment step is already biased toward a certain phenotype, even highly refined downstream imaging cannot recover the cells that were excluded at the start. The value of negative selection lies in removing interfering normal blood cells first, preserving a broader target population, and then using automated staining, imaging, and interpretation for the remaining cells. That is why different CTC platforms can produce very different risk signals even when they are all nominally measuring “CTCs”.
For clinical follow-up, the implication is clear: if the goal is to understand metastatic risk and recurrence monitoring in breast cancer, the platform should not only try to capture cells, but should preserve the phenotypes that are truly associated with disease progression. In that context, CSV+ CTCs may become an important biomarker for metastatic-risk stratification and recurrence monitoring.
Original paper: https://doi.org/10.3390/diseases14040130